论文部分内容阅读
目的了解癫患者抗癫药物使用情况,为合理使用抗癫药提供依据。方法采用回顾性调查方法,分析2002年9~12月住院的53例癫患者病历,对患者的一般情况、药物治疗情况和药物不良反应进行统计和分析。结果入选患者病情好转46例(86.79%),未愈7例(13.21%)。使用的抗癫药物主要有7种,分别是丙戊酸钠、卡马西平、苯巴比妥、苯妥英钠、氯硝西泮、托吡酯和拉莫三嗪。所有入选的患者均联合使用抗癫药,其中35例(66.04%)合并使用两种抗癫药,12例(22.64%)联合使用3种抗癫药,4例(9.43%)联合使用4种抗癫药,另有1例患者同时使用5种抗癫药。共监测到药物不良反应3例,其中卡马西平引起的药物不良反应2例,包括白细胞降低和转氨酶升高各1例;另外丙戊酸引起转氨酶升高1例。结论该院住院癫患者的用药基本合理。临床抗癫治疗时应加强对患者进行用药宣传,规范抗癫药使用,注意监测药物浓度和不良反应,合理联合用药,以保证癫患者的用药安全,提高疗效。
Objective To understand the use of antiepileptic drugs in patients with epilepsy and provide the basis for rational use of antiepileptic drugs. Methods A retrospective survey was conducted to analyze the medical records of 53 cases of epilepsy hospitalized from September to December in 2002. The general situation, drug treatment and adverse drug reactions were statistically analyzed. Results The selected patients improved in 46 cases (86.79%), healed in 7 cases (13.21%). The main anti-epileptic drugs used are seven kinds, namely sodium valproate, carbamazepine, phenobarbital, phenytoin, clonazepam, topiramate and lamotrigine. Antiepileptic drugs were used in all patients, including 35 cases (66.04%) combined with two kinds of antiepileptic drugs, 12 cases (22.64%) combined with 3 kinds of antiepileptic drugs and 4 cases (9.43%) with 4 kinds of antiepileptic drugs Antiepileptic drugs, while another 1 patient also used 5 kinds of antiepileptic drugs. A total of 3 cases of adverse drug reactions were detected, including carbamazepine-induced adverse drug reactions in 2 cases, including leukopenia and elevated transaminases in 1 case; additionally valproic acid caused by elevated transaminase in 1 case. Conclusion The hospitalized patients with epilepsy medication basically reasonable. Clinical anti-epilepsy treatment should be strengthened to promote the use of drugs for patients to regulate the use of antiepileptic drugs, pay attention to monitoring drug concentrations and adverse reactions, a reasonable combination of drugs to ensure that patients with epilepsy medication safety and improve efficacy.